PSMD2
PSMD2 (26S proteasome non-ATPase regulatory subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Overview
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.94, genetic association 0.00, clinical 0.99).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PSMD2 (26S proteasome non-ATPase regulatory subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
- 1 · What it is
PSMD2 (26S proteasome non-ATPase regulatory subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
- 2 · What goes wrong in cancer
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins.
- 3 · How drugs use it
No product in this corpus aims at PSMD2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:9559 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13200 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000175166 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: plasma cell myeloma 0.60, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
Biology
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. Binds to the intracellular domain of tumour necrosis factor type 1 receptor. The binding domain of TRAP1 and TRAP2 resides outside the death domain of TNFR1. Locus 3q27.1 (HGNC).
- Multiple myeloma: Open Targets association 0.60 with plasma cell myeloma (MONDO_0009693)
- Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908)
- Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PSMD2" OR ABSTRACT:"PSMD2" OR TITLE:"proteasome 26S subunit ubiquitin receptor, non-ATPase 2" OR ABSTRACT:"proteasome 26S subunit ubiquitin receptor, non-ATPase 2" OR TITLE:"26S proteasome non-ATPase regulatory subunit 2" OR ABSTRACT:"26S proteasome non-ATPase regulatory subunit 2" OR TITLE:"S2" OR ABSTRACT:"S2" OR TITLE:"P97" OR ABSTRACT:"P97" OR TITLE:"TRAP2" OR ABSTRACT:"TRAP2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PSMD2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetADRM1
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA1
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA2
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA3
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA4
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA5
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA6
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA7
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.